Dudediligence.

Immunome, Inc

IMNMNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.9MSep ’24$2.7MDec ’24$2.9MMar ’25$4.0MJun ’25$0.00Sep ’25$0.00Dec ’25$0.00Mar ’26$0.00Jun ’26
Net income, by quarter
−$47.1MSep ’24−$80.2MDec ’24−$41.6MMar ’25−$43.4MJun ’25−$57.5MSep ’25−$69.9MDec ’25−$53.8MMar ’26−$73.1MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on file$14.0M$9.0M$6.9M
Operating income−$25.2M−$36.9M−$109.5M−$305.8M−$224.1M
Net income−$24.7M−$36.9M−$106.8M−$293.0M−$212.4M
Operating cash flow−$18.2M−$28.7M−$7.6M−$110.8M−$190.9M
Free cash flow−$18.3M−$28.9M−$8.4M−$118.0M−$200.6M
Cash$49.2M$20.3M$98.7M$143.4M$653.5M
Shares outstanding12.1M12.1M43.3M64.5M113.1M